You are here

Approvals, Launches, and New Indications

First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
First New Medication for Seizure Clusters in More Than Two Decades
Averts Disease Worsening, Reduces Potential for Blindness
FDA Removes Boxed Warning With Drug’s Fifth Approval
Kadcyla Cut Risk of Recurring Disease by Half Compared to Herceptin
First Medicines for Adults With Wild-type or Hereditary ATTR-CM
Rare Disorder Typically Co-occurs With Cancer
Global Incidence of Mosquito-Borne Disease Has Increased
Mavyret Now Approved for Adults and Children Over 12
Study Safety Data Support Early Treatment of Underlying Cause of CF
Phase 3 Study Confirmed Drug’s Comparable Safety and Efficacy
Minimally Invasive Method Reduces Regurgitation and Leaking
Medical Device Enables Nerve Stimulation During Sleep
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential
Dovato Achieved Non-inferior Efficacy Compared to Traditional Regimen; No Cases of Resistance
LAMA/LABA Population Expected to Grow Rapidly in Coming Years
Approximately 250,000 People in the U.S. Live with PI
Majority of Trial Patients Achieved Normal Testoserone Levels
Trial Showed Mayzent Reduced Disability Progression, Relapses 
Patients With Implant Saw Improved Walking Distance
First and Only Treatment Reduces Depressive Symptoms Within Days
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
For Locally Advanced or Metastatic Triple-Negative Type Only
Subcutaneous Extended-Release Injectable With Risperidone Now Available in the U.S.
Treatment Options Are Limited After Failure of First- and Second-line Therapies